No clinical benefit from modulating high triglyceride levels and low high-density–lipoprotein cholesterol levels with fibrates has been firmly established, though benefit for patients with diabetes and mixed dyslipidemia remains possible.
No takes yet. Share an insight, caveat, or question.
Goldfine et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: